Barclays Capital Reiterates “Overweight” Rating for Bodycote PLC (LON:BOY) Stock; Athenahealth (ATHN) Has 1.09 Sentiment

Today, Tuesday, 16 January, Bodycote PLC (LON:BOY) stock “Overweight” was maintained by Analysts at Barclays Capital in a report.

athenahealth, Inc., together with its subsidiaries, provides network medical record, revenue cycle, patient engagement, care coordination, and population health services for medical groups and health systems. The company has market cap of $5.18 billion. It offers athenaCollector, a network-enabled billing and practice management solution; athenaClinicals, an electronic health record for electronic health record management to help manage patientÂ’s clinical documentation; athenaCommunicator, an engagement and communication solution that provides an automated communication service between patients and well-known provider practices for interactions outside the exam room; and athenaCoordinator for order transmission and care coordination services. It has a 168.36 P/E ratio. The firm also provides athenahealth Population Health, a cloud population health service; and Epocrates service that include clinical information and decision support services in the areas of drug and disease information, medical calculator and tools, clinical guidelines, clinical messaging, and market research.

Barton Investment Management holds 6.98% of its portfolio in athenahealth, Inc. for 236,819 shares. Pura Vida Investments Llc owns 59,800 shares or 3.73% of their US portfolio. Moreover, Riverbridge Partners Llc has 2.4% invested in the company for 981,741 shares. The California-based Avalon Global Asset Management Llc has invested 2.17% in the stock. Nikko Asset Management Americas Inc., a New York-based fund reported 282,600 shares.

Ratings analysis reveals 40% of athenaHealth’s analysts are positive. Out of 5 Wall Street analysts rating athenaHealth, 2 give it “Buy”, 1 “Sell” rating, while 2 recommend “Hold”. The lowest target is $110.0 while the high is $130.0. The stock’s average target of $120 is -7.31% below today’s ($129.47) share price. ATHN was included in 5 notes of analysts from October 14, 2016. KeyBanc Capital Markets upgraded the stock to “Overweight” rating in Wednesday, January 4 report. The firm earned “Buy” rating on Friday, December 2 by Dougherty & Company. As per Friday, October 28, the company rating was downgraded by JP Morgan. The rating was downgraded by Morgan Stanley to “Equal-Weight” on Wednesday, October 26. The stock has “Underperform” rating by Jefferies on Friday, October 14.

Since January 1, 0001, it had 0 insider buys, and 13 sales for $3.81 million activity.

The stock decreased 2.40% or $3.18 during the last trading session, reaching $129.47. About 509,317 shares traded or 10.10% up from the average. athenahealth, Inc. (ATHN) has risen 0.90% since January 16, 2017 and is uptrending. It has underperformed by 15.80% the S&P500.

Analysts await athenahealth, Inc. (NASDAQ:ATHN) to report earnings on February, 1. They expect $0.46 EPS, up 9.52% or $0.04 from last year’s $0.42 per share. ATHN’s profit will be $18.41M for 70.36 P/E if the $0.46 EPS becomes a reality. After $0.38 actual EPS reported by athenahealth, Inc. for the previous quarter, Wall Street now forecasts 21.05% EPS growth.

Bodycote plc provides thermal processing services worldwide. The company has market cap of 1.90 billion GBP. The firm operates in two business areas, Aerospace, Defence & Energy; and Automotive & General Industrial. It has a 24.63 P/E ratio. It offers heat treatment services, including altering the microstructure of metals and alloys, such as steel and aluminum to impart properties comprising surface hardness, temperature resistance, ductility, and strength; metal joining services consisting of electron beam welding, and vacuum and honeycomb brazing; and Hot isostatic pressing services, including HIP product fabrication, isostatic pressing, and HIP supporting services.

The stock increased 1.68% or GBX 16.5 during the last trading session, reaching GBX 1000. About 42,441 shares traded. Bodycote plc (LON:BOY) has 0.00% since January 16, 2017 and is . It has underperformed by 16.70% the S&P500.

Among 22 analysts covering Bodycote PLC (LON:BOY), 14 have Buy rating, 2 Sell and 6 Hold. Therefore 64% are positive. Bodycote PLC has GBX 1050 highest and GBX 500 lowest target. GBX 793.24’s average target is -20.68% below currents GBX 1000 stock price. Bodycote PLC had 153 analyst reports since July 30, 2015 according to SRatingsIntel. The company was downgraded on Friday, July 29 by Numis Securities. The stock of Bodycote plc (LON:BOY) has “Hold” rating given on Tuesday, February 21 by HSBC. The rating was maintained by Jefferies on Thursday, December 17 with “Buy”. The rating was maintained by Numis Securities on Friday, July 31 with “Add”. RBC Capital Markets maintained Bodycote plc (LON:BOY) rating on Tuesday, December 8. RBC Capital Markets has “Sector Perform” rating and GBX 730 target. UBS maintained Bodycote plc (LON:BOY) on Tuesday, October 27 with “Buy” rating. The rating was maintained by Canaccord Genuity with “Buy” on Tuesday, November 17. The stock of Bodycote plc (LON:BOY) has “Buy” rating given on Wednesday, November 18 by Numis Securities. Morgan Stanley maintained it with “Overweight” rating and GBX 720 target in Friday, August 5 report. The firm has “Underweight” rating by JP Morgan given on Monday, July 4.